Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Management Guidelines for Chronic Obstructive Pulmonary Disease

  • Chapter
  • First Online:
COPD

Part of the book series: Respiratory Medicine ((RM))

  • 5621 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Celli BR, MacNee W (2004) Standards for the diagnosis and treatment of COPD. Eur Respir J 23:932–946

    Article  CAS  PubMed  Google Scholar 

  2. Global Obstructive Lung Disease Initiative. www.GOLD.org (updated 2006)

  3. American Thoracic Society (1995) Standards for the diagnosis and case of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 152:78–121

    Google Scholar 

  4. Pauwels RA et al (2001) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 163(5):1256–1276

    CAS  PubMed  Google Scholar 

  5. Celli BR, Cote CG, Marin JM, Casanova C, de Montes Oca M, Mendez RA, Pinto Plata V, Cabral HJ (2004) The body mass index, airflow obstruction, dyspnea and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 350:1005–1012

    Article  CAS  PubMed  Google Scholar 

  6. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE (2005) Lung Health Study Research Group. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 142:233–239

    PubMed  Google Scholar 

  7. McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA (May 2007) TORCH Clinical Endpoint Committee. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax 62(5):411–415

    Article  PubMed  Google Scholar 

  8. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC (2002) Chronic obstructive pulmonary disease surveillance – United States, 1971–2000. MMWR 51:1–16

    Google Scholar 

  9. Celli BR, Halbert RJ, Isonaka S, Schau B (2003) Population impact of different definitions of airways obstruction. Eur Respir J 22:268–273

    Article  CAS  PubMed  Google Scholar 

  10. Menezes A, Perez-Padilla R, Jardim J, Muiño A, Lopez M, Valdivia G, Montes de Oca M, Talamo C, Hallal P, Victoria C (2005) Prevalence of chronic obstructive pulmonary disease in five Latin American cities: the PLATINO study. Lancet 366:1875–1881

    Article  PubMed  Google Scholar 

  11. Pena VS, Miravitlles M, Gabriel R, Jimenez-Ruiz CA, Villasante C, Masa JF, Viejo JL, Fernandez-Fau L (2000) Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study. Chest 118:981–989

    Article  CAS  PubMed  Google Scholar 

  12. Tzanakis N, Anagnostopoulou U, Filaditaki V, Christaki P, Siafakas N (2004) COPD group of the Hellenic Thoracic Society Prevalence of COPD in Greece. Chest 125:892–900

    Article  PubMed  Google Scholar 

  13. de Marco R, Accordini S, Cerveri I, Corsico A, Sunyer J, Neukirch F, Kunzli N, Leynaert B, Janson C, Gislason T, Vermeire P, Svanes C, Anto JM, Burney P (2004) European Community Respiratory Health Survey Study Group. An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. Thorax 59:120–125

    Article  PubMed  Google Scholar 

  14. Talamo C, de Oca MM, Halbert R, Perez-Padilla R, Jardim JR, Muino A, Lopez MV, Valdivia G, Pertuze J, Moreno D, Menezes AM; PLATINO team (2007) Diagnostic labeling of COPD in five Latin American cities. Chest 131:60–67

    Google Scholar 

  15. Damarla M, Celli B, Mullerova H, Pinto-Plata V (2006) Discrepancy in the use of confirmatory tests in patients hospitalized with the diagnosis of chronic obstructive pulmonary disease or congestive heart failure. Respir Care 51:1120–1124

    PubMed  Google Scholar 

  16. Rennard S, Decramer M, Calverley PM, Pride NB, Soriano JB, Vermeire PA, Vestbo J (2002) Impact of COPD in North America and Europe in 2000: subjects’ perspective of Confronting COPD International Survey. Eur Respir J 20:799–805

    Article  CAS  PubMed  Google Scholar 

  17. Anthonisen NR, Connett JE, Kiley JP, Altose M, Bailey W, Sonia Buist A, Conway W, Enright P, Kanner R, O’Hara P, Owens G, Scanlon P, Tashkin D, Wise R (1994) Effect of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the lung health study. JAMA 272:1497–1505

    Article  CAS  PubMed  Google Scholar 

  18. Casaburi R, Mahler D, Jones P, Wanner A, SanPedro G, ZuWallack R, Menjoge S, Serby C, Witek T (2002) A long term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 19:217–224

    Article  CAS  PubMed  Google Scholar 

  19. Mahler D, Donohue J, Barbee R, Goldman M, Gross N, Wisnewiski M, Yancey S, Zakes B, Rickard K, Anderson W (1999) Efficacy of salmeterol xinoafate in the treatment of COPD. Chest 115:957–965

    Article  CAS  PubMed  Google Scholar 

  20. Jones P, Bosh T (1997) Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 155:1283–1289

    CAS  PubMed  Google Scholar 

  21. Vincken W, van Noord J, Greefhorst A, Bantje Th, Kesten S, Korducki L, Cornelissen P (2002) On behalf of the Dutch/Belgian tiotropium study group. Improved health outcome in patients with COPD during 1 year treatment with tiorpium. Eur Respir J 19:209–216

    Article  CAS  PubMed  Google Scholar 

  22. ZuWallack R, Mahler D, Reilly D et al (2001) Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 119:1628–1630

    Article  Google Scholar 

  23. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK (2000) Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 320:1297–1303

    Article  CAS  PubMed  Google Scholar 

  24. The Lung Health Study Research Group (2000) Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 343:1902–1909

    Article  Google Scholar 

  25. Hay JG, Stone P, Carter J, Church S, Eyre-Brook A, Pearson MG, Woodcock AA, Calverley PM (1992) Bronchodilator reversibility, exercise performance and breathlessness in stable chronic obstructive pulmonary disease. Eur Respir J 5:659–664

    CAS  PubMed  Google Scholar 

  26. Friedman M, Serby C, Menjoge S, Wilson J, Hilleman D, Witek T (1999) Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest 115:635–641

    Article  CAS  PubMed  Google Scholar 

  27. Belman MJ, Botnick WC, Shin JW (1996) Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 153:967–975

    CAS  PubMed  Google Scholar 

  28. O’Donnell D, Lam M, Webb K (1999) Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 160:542–549

    PubMed  Google Scholar 

  29. O’Donnell D, Voduc N, Fitzpatrick M, Webb K (2004) Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J 24:86–94

    Article  PubMed  CAS  Google Scholar 

  30. O’Donnell D, Flugre T, Gerken F, Hamilton A, Webb K, Aguilaniu B et al (2004) Effects of tiotropium on lung hyperinflation, dyspnea and exercise tolerance in COPD. Eur Respir J 23:832–840

    Article  PubMed  CAS  Google Scholar 

  31. Marin J, Carrizo S, Gascon M, Sanchez A, Gallego B, Celli B (2001) Inspiratory capacity, dynamic hyperinflation, breathlessness and exercise performance during the 6 minute walk test in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 163:1395–1400

    CAS  PubMed  Google Scholar 

  32. Martinez F, Montes de Oca M, Whyte R, Stetz J, Gay S, Celli B (1997) Lung-volume reduction surgery improves dyspnea, dynamic hyperinflation and respiratory muscle function. Am J Respir Crit Care Med 155:2018–2023

    Google Scholar 

  33. Casanova C, Cote C, de Torres JP, Aguirre-Jaime A, Marin JM, Pinto-Plata V, Celli BR (2005) Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 171:591–597, 15 Mar 2005

    Article  PubMed  Google Scholar 

  34. Agustí AG, Noguera A, Sauleda J et al (2003) Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 21:347–360

    Article  PubMed  Google Scholar 

  35. Nishimura K, Izumi T, Tsukino M, Oga T (2002) Dyspnea is a better predictor of 5-Year survival than airway obstruction in patients with COPD. Chest 121:1434–1440

    Article  PubMed  Google Scholar 

  36. Schols AM, Slangen J, Volovics L, Wouters EF (1998) Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157:1791–1797

    CAS  PubMed  Google Scholar 

  37. Landbo C, Prescott E, Lange P, Vestbo J, Almdal TP (1999) Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 160:1856–1861

    CAS  PubMed  Google Scholar 

  38. Gerardi DA, Lovett L, Benoit-Connors ML, Reardon JZ, ZuWallack RL (1996) Variables related to increased mortality following out-patient pulmonary rehabilitation. Eur Respir J 9:431–435

    Article  CAS  PubMed  Google Scholar 

  39. Pinto-Plata VM, Cote C, Cabral H, Taylor J, Celli BR (2004) The 6-minute walk distance: change over time and value as a predictor of survival in severe COPD. Eur Respir J 1:28–33

    Article  Google Scholar 

  40. Cote CG, Dordelly LJ, Celli BR (2007) Impact of chronic obstructive pulmonary disease exacerbations on patient centered outcomes. Chest 131(3):696–704

    Article  PubMed  Google Scholar 

  41. Imsfeld S, Bloch KE, Weder W, Russi EW (2006) The BODE index after lung volume reduction surgery correlates with survival. Chest 129:835–836

    Article  Google Scholar 

  42. Nocturnal Oxygen Therapy Trial Group (1980) Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease. Ann Intern Med 93:391–398

    Google Scholar 

  43. Report of the Medical Research Council Working Party (1981) Long-term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1:681–685

    Google Scholar 

  44. Brochard L, Mancebo J, Wysocki M et al (1995) Noninvasive ventilation for acute exacerbation of chronic obstructive pulmonary disease. N Engl J Med 333:817–822

    Article  CAS  PubMed  Google Scholar 

  45. Kramer N, Meyer T, Meharg J, Cece R, Hill NS (1995) Randomized prospective trial of non-invasive positive pressure ventilation in acute respiratory failure. Am J Respir Crit Care Med 151:1799–1806

    CAS  PubMed  Google Scholar 

  46. Bott J, Caroll P, Conway J et al (1993) Randomized controlled trial of nasal ventilation in acute ventilatory failure due to obstructive lung disease. Lancet 341:1555–1559

    Article  CAS  PubMed  Google Scholar 

  47. National Emphysema Treatment Trial Research Group (2003) A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 348:2059–2073

    Article  Google Scholar 

  48. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J (2007) TORCH investigators. Salmetrol abd fluticasone propionate and survival in chronic obstructive pulmonary disease. N Eng J Med 356:775–789, 22 Feb

    Article  CAS  Google Scholar 

  49. Nici L, Donner C, Wouters E, Zuwallack R, Ambrosino N, Bourbeau J, Carone M, Celli B, Engelen M, Fahy B, Garvey C, Goldstein R, Gosselink R, Lareau S, MacIntyre N, Maltais F, Morgan M, O’Donnell D, Prefault C, Reardon J, Rochester C, Schols A, Singh S, Troosters T (2006) ATS/ERS Pulmonary Rehabilitation Writing Committee. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med 173:1390–1413

    Article  PubMed  Google Scholar 

  50. Ries AL, Kaplan RM, Limberg TM, Prewitt LM (1995) The effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease. Ann Intern Med 122:823–832

    CAS  PubMed  Google Scholar 

  51. Kottke TE, Battista RN, DeFriese GH (1988) Attributes of successful smoking cessation interventions in medical practice: a meta-analysis of 39 controlled trials. JAMA 259:2882–2889

    Article  Google Scholar 

  52. Fiore M, Bailey W, Cohen S, Dorfman S, Goldstein M, Gritz E, Heyman R, Jaen C, Kottke T, Lando H, Mecklenburg R, Mullen P, Nett L, Robinson L, Sistzer M, Tommasello A, Villejo L, Wewers M (June 2000) Treating Tobacco use and dependence. U.S. Department Of Health and Human Services, Rockville

    Google Scholar 

  53. Jorenby DE, Leischow SG, Nides MA et al (1999) A controlled trial of sustained release buproprion, a nicotine patch or both for smoking cessation. N Engl J Med 340:685–691

    Article  CAS  PubMed  Google Scholar 

  54. Keating GM, Siddiqui MA (2006) Varnicline: a review of its use as an aid to smoking cessation therapy. CNS Drugs 20:945–980

    Article  CAS  PubMed  Google Scholar 

  55. Celli B, ZuWallack R, Wang S, Kesten S (Nov 2003) Improvement of inspiratory capacity and hyperinflation with tiotropium in COPD patients with severe hyperinflation. Chest 124(5):1743–1748

    Article  PubMed  Google Scholar 

  56. O’Donnell DE, Sciurba F, Celli B, Mahler DA, Webb KA, Kalberg CJ, Knobil K (2006) Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest 130:647–656

    Article  PubMed  Google Scholar 

  57. Dahl R, Greefhorst LA, Nowak D, Nonikov V, Byrne AM, Thomson MH, Till D, Della CG (2001) Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164:778–784

    CAS  PubMed  Google Scholar 

  58. Tantucci C, Duguet A, Similowski T, Zelter M, Derenne J-P, Milic-Emili J (1998) Effect of salbutamol on dynamic hyperinflation in chronic obstructive pulmonary disease patients. Eur Respir J 12:799–804

    Article  CAS  PubMed  Google Scholar 

  59. Rennard SI, Anderson W, ZuWallack R, Broughton J, Bailey W, Friedman M, Wisniewski M, Rickard K (2001) Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med Apr 163(5):1087–1092, 163:1087–1092

    CAS  Google Scholar 

  60. Ramirez-Venegas A, Ward J, Lentine T, Mahler D (1997) Salmeterol reduces dyspnea and improves lung function in patients with COPD. Chest 112:336–340

    Article  CAS  PubMed  Google Scholar 

  61. Niwehowener D, Rice K, Cote C, Paulson D, Cooper JA, Korducki L et al (2005) Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once daily anticholinergic: a randomized trial. Ann Intern Med 143:317–326

    Google Scholar 

  62. Van Noord J, Aumann J, Jasnseens E, Smeets J, Verhaert J, Disse B et al (2005) omparison of tiotropium q.d, formoterol bid and both combined qd in patients with COPD. Respir J 26:214–222

    Article  CAS  Google Scholar 

  63. Decramer M, Celli B, Tashkin D, Pawels R, Burkhart D, Cassino C, Kesten S (2004) Clinical trial design considerations in assessing long-term functional impacts of Tiotropium. J COPD 1:303–312

    Article  Google Scholar 

  64. COMBIVENT Inhalation Aerosol Study Group (1994) In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest 105:1411–1419

    Article  Google Scholar 

  65. Karpel JP, Kotch A, Zinny M, Pesin J, Alleyne W (1994) A comparison of inhaled ipratropium, oral theophylline plus inhaled β-agonist, and the combination of all three in patients with COPD. Chest 105:1089–1094

    Article  CAS  PubMed  Google Scholar 

  66. Barnes PJ, Ito K, Adcock IM (2004) Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet 363:731–733

    Article  CAS  PubMed  Google Scholar 

  67. Rabe K, Bateman E, O’Donnell D, Witte S, Bredenbroker D, Bethke T (2005) Roflumilast- an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 366:563–571

    Article  CAS  PubMed  Google Scholar 

  68. Rennard S, Schachter N, Strek M, Rickard K, Amit O (2006) Cilomilast for COPD: results of a 6-month, placebo controlled study of a potent, selective inhibitor of posphodiesterase 4. Chest 129:56–66

    Article  CAS  PubMed  Google Scholar 

  69. Mahler D, Huang S, Tabrizzi M, Bell G (2004) Efficacy and safety of a monoclonal antibody recognizing interleukin – 8 in COPD: a pilot study. Chest 126:926–934

    Article  CAS  PubMed  Google Scholar 

  70. Rennard S, Fogarty C, Kelsen S, Long W, Ramsdell J, Allison J et al (2007) The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175:926–934

    Article  CAS  PubMed  Google Scholar 

  71. Vestbo J, TORCH Study Group (2004) The TORCH (towards a revolution in COPD health) survival study protocol. Eur Respir J 24:206–210

    Article  CAS  PubMed  Google Scholar 

  72. Pauwels R, Lofdahl C, Laitinen L, Schouten J, Postma D, Pride N, Ohlson S (1999) Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 340:1948–1953

    Article  CAS  PubMed  Google Scholar 

  73. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K (1999) Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised trial. Lancet 353:1819–1823

    Article  CAS  PubMed  Google Scholar 

  74. Sin DD (2001) Tu JV Inhaled corticosteroids and the risk for mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164:580–584

    CAS  PubMed  Google Scholar 

  75. Soriano JB, Vestbo J, Pride N, Kin V, Maden C, Maier WC (2002) Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J 20:819–824

    Article  CAS  PubMed  Google Scholar 

  76. Calverley PM, Boonsawat W, Cseke Z et al (2003) Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 22:912–919

    Article  CAS  PubMed  Google Scholar 

  77. Szafranski W, Cukier A, Ramirez A et al (2003) Efficacy and safety of budesonide/formoterol in the management of COPD. Eur Respir J 21:74–81

    Article  CAS  PubMed  Google Scholar 

  78. Cazzola M, Dahl R (2004) Inhaled combination therapy with inhaled long-acting beta-2-agonist and corticosteroids in stable COPD. Chest 126:220–237

    Article  CAS  PubMed  Google Scholar 

  79. Aaron S, Vandemheen KL, Fergusson D, Maltais F, Borbeau J, Goldstein R et al (2007) Tiotropium in combination with placebo, salmeterol or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 146(8):545–555

    PubMed  Google Scholar 

  80. Petty TL (1990) The National Mucolytic Study: results of a randomized, double-blind, placebo-controlled study of iodinated glycerol in chronic obstructive bronchitis. Chest 97:75–83

    Article  CAS  PubMed  Google Scholar 

  81. Decramer M, Rutten-van Molken M, Dekhuijzen PN, Troosters T, van Herwaarden C, Pellegrino R, van Schayck CP, Olivieri D, Del Donno M, De Backer W, Lankhorst I, Ardia A (2005) Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 365(9470):1552–1560, 30 Apr–6 May

    Article  CAS  PubMed  Google Scholar 

  82. Anthonisen NR, Manfreda J, Warren CPW, Hershfield ES, Harding GKM, Nelson NA (1987) Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Int Med 106:196–204

    CAS  PubMed  Google Scholar 

  83. Saint S, Bent S, Vittinghoff F, Grady D (1995) Antibiotics in chronic obstructive pulmonary disease exacerbation. A metanalysis. JAMA 273:957–960

    Article  CAS  PubMed  Google Scholar 

  84. Stockley R, O’Bryan C, Pie A, Hill S (2000) Relationship of sputum color to nature and outpatient management of acute exacerbation of COPD. Chest 117:1638–1645

    Article  CAS  PubMed  Google Scholar 

  85. Miravitlles M (2002) Epidemiology of chronic obstructive pulmonary disease exacerbations. Clin Pulm Med 9(4):191–197

    Article  Google Scholar 

  86. Adams SG, Melo J, Luther M, Anzueto A (2000) Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest 117:1345–1352

    Article  CAS  PubMed  Google Scholar 

  87. Dirksen A, Dijkman JH, Madsen F, Stoel B, Hutchison DC, Ulrik CS, Skovgaard LT, Kok-Jensen A, Rudolphus A, Seersholm N, Vrooman HA, Reiber JH, Hansen NC, Heckscher T, Viskum K, Stolk J (1999) A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med 160:1468–1472

    CAS  PubMed  Google Scholar 

  88. Sandhaus R (2004) Alpha-1-antitrypsin deficiency: new and emerging therapies for alpha-1antytripsin deficiency. Thorax 59:904–909

    Article  CAS  PubMed  Google Scholar 

  89. Nichol KL, Baken L, Nelson A (1999) Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. Ann Intern Med 130:397–403

    CAS  PubMed  Google Scholar 

  90. Nichol KL, Mendelman PM, Mallon KP, Jackson LA, Gorse GJ, Belshe RB, Glezen WP, Wittes J (1999) Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 282:137–144

    Article  CAS  PubMed  Google Scholar 

  91. Snider G (1996) Reduction pneumoplasty for giant bullous emphysema Implications for surgical treatment of nonbullous emphysema. Chest 109:540–548

    Article  CAS  PubMed  Google Scholar 

  92. Patterson G, Maurer J, Williams T, Cardoso P, Scavuzzo M, Todd T (1999) Comparison of outcomes of double and single lung transplantation for obstructive lung disease. J Thorac Cardiovasc Surg 110:623–632

    Google Scholar 

  93. Bando K, Paradis I, Keenan R et al (1995) Comparison of outcomes after single and bilateral lung transplantation for obstructive lung disease. J Heart Lung Transplant 14:692–698

    CAS  PubMed  Google Scholar 

  94. Orens J, Becker F, Lynch J III, Christensen P, Deeb G, Martinez F (1995) Cardiopulmonary exercise testing following allogeneic lung transplantation for different underlying disease states. Chest 107:144–149

    Article  CAS  PubMed  Google Scholar 

  95. Hosenpud J, Bennett L, Keck B, Boucek M, Novick R (2001) The registry of the International Society for Heart and Lung Transplantation: eighteenth official report-2001. J Heart Lung Transplant 20:805–815

    Article  CAS  PubMed  Google Scholar 

  96. Orens JB, Estenne M, Arcasoy S, Conte JV, Corris P, Egan JJ, Egan T, Keshavjee S, Knoop C, Kotloff R, Martinez FJ, Nathan S, Palmer S, Patterson A, Singer L, Snell G, Studer S, Vachiery JL, Glanville AR (2006) Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. International guidelines for the selection of lung transplant candidates: 2006 update – a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 25:745–575

    Article  PubMed  Google Scholar 

  97. Cooper J, Patterson G, Sundaresan R, Trulock E, Yusen R, Pohl M, Lefrak S (1996) Results of 150 consecutive bilateral lung volume reduction procedures in patients with severe emphysema. J Thorac Cardiovasc Surg 112:1319–1330

    Article  CAS  PubMed  Google Scholar 

  98. Leyenson V, Furukawa S, Kuzma AM, Cordova F, Travaline J, Criner GJ (2000) Correlation of changes in quality of life after lung volume reduction surgery with changes in lung function, exercise, and gas exchange. Chest 118(3):728–735

    Article  CAS  PubMed  Google Scholar 

  99. Geddes D, Davies M, Koyama H, Hansell D, Pastorino U, Pepper J, Agent P, Cullinan P, MacNeill S, Goldstraw P (2000) Effect of lung-volume-reduction surgery in patients with severe emphysema. N Eng J Med 343:239–245

    Article  CAS  Google Scholar 

  100. Criner G, Cordova G, Furukawa S, Kuzma A, Travaline J, Leyenson V, O’Brien G (1999) Prospective randomized trial comparing bilateral lung volume reduction surgery to pulmonary rehabilitation in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 160:2018–2027

    CAS  PubMed  Google Scholar 

  101. Flaherty KR, Kazerooni EA, Curtis JL et al (2000) Short-term and long-term outcomes after bilateral lung volume reduction surgery: prediction by quantitative CT. Chest 119:1337–1346

    Article  Google Scholar 

  102. Celli BR, Montes de Oca M, Mendez R et al (1997) Lung reduction surgery in severe COPD decreases central drive and ventilatory response to CO2. Chest 112:902–906

    Article  CAS  PubMed  Google Scholar 

  103. Flaherty KR, Kazerooni EA, Curtis JL, Iannettoni M, Lange L, Schork MA, Martinez FJ (2001) Short-term and long-term outcomes after bilateral lung volume reduction surgery: prediction by quantitative CT. Chest 119(5):1337–1346

    Article  CAS  PubMed  Google Scholar 

  104. National Emphysema Treatment Trial Research Group (NETT Research Group) (2001) Patients at high risk of death after lung-volume-reduction surgery. N Engl J Med 345:1075–1083

    Article  Google Scholar 

  105. Szekely LA, Oelberg DA, Wright C et al (1997) Preoperative predictors of operative morbidity and mortality in COPD patients undergoing bilateral lung volume reduction surgery. Chest 111:550–558

    Article  CAS  PubMed  Google Scholar 

  106. Glaspole IN, Gabbay E, Smith JA, Rabinov M, Snell GI (2000) Predictors of perioperative morbidity and mortality in lung volume reduction surgery. Ann Thorac Surg 69:1711–1716

    Article  CAS  PubMed  Google Scholar 

  107. Hopkinson NS, Toma TP, Hansell DM, Goldstraw P, Moxham J, Geddes DM, Polkey MI (2005) Effect of bronchoscopic lung volume reduction on dynamic hyperinflation and exercise in emphysema. Am J Respir Crit Care Med 17:453–460

    Google Scholar 

  108. Ingenito EP, Loring SG, Moy ML et al (2001) Comparison of physiological and radiological screening for lung volume reduction surgery. Am J Respir Crit Care Med 163:1068–1073

    CAS  PubMed  Google Scholar 

  109. Ingenito EP, Reilly JJ, Mentzer SJ, Swanson SJ, Vin R, Keuhn H, Berger RL, Hoffman A (2001) Bronchoscopic volume reduction: a safe and effective alternative to surgical therapy for emphysema. Am J Respir Crit Care Med 164(2):295–301

    CAS  PubMed  Google Scholar 

  110. Reilley J, Chest Reilly J, Washko G, Pinto-Plata V, Velez E, Kenney L, Berger R, Celli B (2007) Biological lung volume reduction: a new bronchoscopic therapy for advanced emphysema. Chest 131:1108–1113

    Article  Google Scholar 

  111. Agusti A, Sauleda J, Miralles C et al (2002) Skeletal muscle apoptosis and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 166:485–489

    Article  PubMed  Google Scholar 

  112. Decramer M, Gosselink R, Troosters T, Verschueren M, Evers G (1997) Muscle weakness is related to utilization of health care resources in COPD patients. Eur Respir J 10:417–423

    Article  CAS  PubMed  Google Scholar 

  113. Reardon J, Awad E, Normandin E et al (1994) The effect of comprehensive outpatient pulmonary rehabilitation on dyspnea. Chest 105:1046–1052

    Article  CAS  PubMed  Google Scholar 

  114. Goldstein RS, Gork EH, Stubbing D et al (1994) Randomized controlled trial of respiratory rehabilitation. Lancet 344:1394–1397

    Article  CAS  PubMed  Google Scholar 

  115. Wykstra PJ, Van Altens R, Kraan J et al (1994) Quality of life in patients with chronic obstructive pulmonary disease improves after rehabilitation at home. Eur Respir J 7:269–273

    Article  Google Scholar 

  116. Bendstrup KE, Ingenman Jensen J, Holm S, Bengtsson B (1997) Out-patient rehabilitation improves activities of daily living, quality of life, and exercise tolerance in chronic obstructive pulmonary disease. Eur Respir J 10:2801–2806

    Article  CAS  PubMed  Google Scholar 

  117. Griffiths TL, Burr ML, Campbell IA, Lewis-Jenkins V, Mullins J, Shields K, Turner-Lawlor PJ, Pyne N, Newcombe RG, Lonescu AA, Thomas J, Turnbridge J (2000) Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomized controlled trial. Lancet 355:362–368

    Article  CAS  PubMed  Google Scholar 

  118. Guell R, Casan P, Belda J, Sangenis M, Morante F, Guyatt G, Sanchis J (2000) Long-term effects of outpatient rehabilitation of COPD: a randomized trial. Chest 117:976–983

    Article  CAS  PubMed  Google Scholar 

  119. Wedzicha JA, Bestall JC, Garrod R, Garnham R, Paul EA, Jones PW (1998) Randomised controlled trial of pulmonary rehabilitation in severe chronic obstructive pulmonary disease patients, stratified with the MRC dyspnoea scale. Eur Respir J 12:363–369

    Article  CAS  PubMed  Google Scholar 

  120. Trooster T, Gosselink R (2000) Decramer M Short and long term effects of outpatients pulmonary rehabilitation in chronic obstructive pulmonary disease: a randomized trial. Am J Med 109:207–212

    Article  Google Scholar 

  121. Maltais F, LeBlanc P, Simard C et al (1996) Skeletal muscle adaptation to endurance training in patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 154:436–444

    Google Scholar 

  122. Ries A, Kaplan R, Myers R, Prewett L (2003) Maintenance after ehabilitation in lung disease. A randomized trial. Am J Respir Crit Care Med 167:880–888

    Article  PubMed  Google Scholar 

  123. Cote CG, Celli BR (2005) Pulmonary rehabilitation and the BODE index in COPD. Eur Respir J 26:630–636

    Article  CAS  PubMed  Google Scholar 

  124. Prigatano GP, Parsons OA, Wright E, Levin DC, Hawryluk G (1983) Neuropsychologic test performance in mildly hypoxemic patients with chronic obstructive pulmonary disease. J Consult Clin Psychol 51:108–116

    Article  CAS  PubMed  Google Scholar 

  125. Grant I, Prigatano GP, Heaton RK, McSweeny AJ, Wright EC, Adams KM (1987) Progressive neuropsychologic impairment and hypoxemia. Relationship in chronic obstructive pulmonary disease. Arch Gen Psychiatry 44:999–1006

    CAS  PubMed  Google Scholar 

  126. Criner GJ, Celli BR (1987) Ventilatory muscle recruitment in exercise with O2 in obstructed patients with mild hypoxemia. J Appl Physiol 63:195–200

    CAS  PubMed  Google Scholar 

  127. Vyas MN, Banister EW, Morton JW, Grzybowski S (1971) Response to exercise in patients with chronic airway obstruction. II. Effects of breathing 40 percent oxygen. Am Rev Respir Dis 103:401–412

    CAS  PubMed  Google Scholar 

  128. Dean NC, Brown JK, Himelman RB, Doherty JJ, Gold WM, Stulbarg MS (1992) Oxygen may improve dyspnea and endurance in patients with chronic obstructive pulmonary disease and only mild hypoxemia. Am Rev Respir Dis 146:941–945

    CAS  PubMed  Google Scholar 

  129. Rodriguez-Roisin R (2000) Toward a consensus definition for COPD exacerbations. Chest 117:398s–401s

    Article  CAS  PubMed  Google Scholar 

  130. Celli B, Barnes P (2007) Exacerbations of chronic obstructive pulmonary disease. Eur Respir J 29:1224–1238

    Article  CAS  PubMed  Google Scholar 

  131. Angus DL, RM CPM (1999) Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomized controlled trial. Lancet 345:456–460

    Google Scholar 

  132. Thompson WH, Nielson CP, Carvalho P et al (1996) Controlled trial of oral prednisone in outpatients with cute COPD exacerbation. Am J Respir Crit Care Med 154:407–412

    CAS  PubMed  Google Scholar 

  133. Nieweohner DE, Erbland ML, Deupree RH et al (1999) Effect of glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med 340:1941–1947

    Article  Google Scholar 

  134. Nouira S, Marghli S, Belghith M, Besbes L, Elatrous S, Abroug F (2001) Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomized placebo-controlled trial. Lancet 358:2020–2035

    Article  CAS  PubMed  Google Scholar 

  135. Seemungal TAR, Donaldson GC, Paul EA et al (1998) Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157:1418–1422

    CAS  PubMed  Google Scholar 

  136. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA (2002) Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 57:847–852

    Article  CAS  PubMed  Google Scholar 

  137. Pinto-Plata V, Livnat G, Girish M, Cabral H, Masdin P, Linacre P, Drew R, Kenney L, Celli B (2007) Systemic cytokine, clinical and physiological changes in patients admitted with exacerbations of COPD. Chest 131:37–43

    Article  CAS  PubMed  Google Scholar 

  138. Casanova C, Celli BR, Tost L, Soriano E, Abreu J, Velasco V, Santolaria F (2000) Long-term controlled trial of nocturnal nasal positive pressure ventilation in patients with severe COPD. Chest 118:1582–1590

    Article  CAS  PubMed  Google Scholar 

  139. Clinic E, Sturani C, Rossi A et al (2002) The Italian multicenter study on non-invasive ventilation in chronic obstructive pulmonary disease patients. Eur Respir J 20:529–538

    Article  Google Scholar 

  140. Barnes PJ, Shapiro S, Pawels R (2003) Chronic obstructive pulmonary disease; molecular and cellular mechanisms. Eur Respir J 22:672–688

    Article  CAS  PubMed  Google Scholar 

  141. Wouters E, Creutzberg E, Schols A (2002) Systemic effects of COPD. Chest 121:127S–130S

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Brigham and Women’s Hospital, Harvard University, Boston, MA, USA

    Bartolome R. Celli

Authors
  1. Bartolome R. Celli
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. , Section of Pulmonary and Critical Care M, Baylor College of Medicine, 1504 Taub Loop, Houston, 77030, Texas, USA

    Nicola A. Hanania

  2. Michael E. DeBakey VA Medical Center, Baylor College of Medicine, 2002 Holcombe Blvd., Houston, 77030, Texas, USA

    Amir Sharafkhaneh

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Celli, B.R. (2011). Management Guidelines for Chronic Obstructive Pulmonary Disease. In: Hanania, N., Sharafkhaneh, A. (eds) COPD. Respiratory Medicine. Humana Press. https://doi.org/10.1007/978-1-59745-357-8_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-357-8_5

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-949-9

  • Online ISBN: 978-1-59745-357-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation